All News

The findings support the potential cardiovascular advantages of the GLP-1RA class in women with PCOS, a population already at increased cardiometabolic risk.

While exercise is beneficial during pregnancy and ACOG recommends 150 mins/week, this is the first study to examine benefits of specific regimen elements on their own.

Postmenopausal women taking fezolinetant experienced positive changes in body fat distribution, increases in which are known to increase risks of cardiometabolic disease.

Elinzanetant reduced VMS frequency and intensity, and improved sleep and quality of life, according to the meta-analysis to be presented at the ACOG 2025 meeting.

The two areas where primary care physicians can contribute to improving women's health, according to Laurence Shields, MD.

Building trust with patients early on will help them feel comfortable discussing their symptoms and treatment preferences, says JoAnn Pinkerton, MD.

Every patient should be offered evidence-based analgesia for pain management for in-office uterine and cervical procedures after shared, trauma-informed decision-making.

Two-thirds of pregnant individuals opted for either maternal vaccination against RSV or for neonatal monoclonal antibody therapy and for other vaccines recommended in pregnancy.

In a cancer survivorship clinic in urban New York, only one-quarter of long-term breast cancer survivors received genetic testing, contrary to current recommendations.

Secnidazole granules reduced recurrence rates to 20% over a period of 28 weeks in a small prospective pilot study, outperforming cumbersome daily regimens.

Your daily dose of the clinical news you may have missed.

The most commonly reported adverse effects of high-dose glucocorticoid therapy were on bone health, cardiometabolic function, and height and growth.

A preview of sessions covering menopause and vasomotor symptoms during ACOG 2025 in Minneapolis, MN.

Your daily dose of the clinical news you may have missed.

The potential cardiovascular impact of prolonged oral corticosteroid therapy in the AD population observed in this study confirms longstanding cautions.

Semaglutide was associated with a significant reduction in risk for major adverse cardiovascular events after just 3 months of treatment in a population with established CVD.